Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R. Pavelka K, et al. Among authors: kotak s. Clin Rheumatol. 2013 Sep;32(9):1275-81. doi: 10.1007/s10067-013-2240-4. Epub 2013 May 11. Clin Rheumatol. 2013. PMID: 23666316 Clinical Trial.
Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, Ferdousi T, Koenig AS, Kotak S, Vlahos B. Machado DA, et al. Among authors: kotak s. J Clin Rheumatol. 2014 Jan;20(1):25-33. doi: 10.1097/RHU.0000000000000055. J Clin Rheumatol. 2014. PMID: 24356474 Clinical Trial.
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.
Damjanov N, Shehhi WA, Huang F, Kotak S, Burgos-Vargas R, Shirazy K, Bananis E, Szumski A, Llamado LJ, Mahgoub E. Damjanov N, et al. Among authors: kotak s. Rheumatol Int. 2016 May;36(5):643-51. doi: 10.1007/s00296-016-3452-0. Epub 2016 Mar 11. Rheumatol Int. 2016. PMID: 26968844 Clinical Trial.
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B. Pavelka K, et al. Among authors: kotak s. Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9. Rheumatol Int. 2017. PMID: 28597306 Clinical Trial.
The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.
Burgos-Varga R, Wei JC, Rahman MU, Akkoc N, Haq SA, Hammoudeh M, Mahgoub E, Singh E, Llamado LJ, Shirazy K, Kotak S, Hammond C, Pedersen R, Shen Q, Vlahos B. Burgos-Varga R, et al. Among authors: kotak s. Arthritis Res Ther. 2016 Jun 7;18(1):132. doi: 10.1186/s13075-016-1027-9. Arthritis Res Ther. 2016. PMID: 27267875 Free PMC article.
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B. Moots RJ, et al. Among authors: kotak s. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017. PLoS One. 2017. PMID: 28448562 Free PMC article.
69 results